English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

. Adverse drug reactions, due at least in part to interindividual variability in drug response, rank between the 4th and 6th leading causes of death in the U.S. The field of “pharmacogenetics” (the study of variability in drug response due to heredity), should help in reducing drug-caused morbidity and mortality[1]. The underlying genetics for the efficacy of the chemotherapeutic treatment of ovarian cancer is still unknown and subject to a high degree of uncertainty and interindividual variability[2]. In the present project, using a pharmacogenomic approach, we evaluate the patient response rates to primary chemotherapeutic treatment of ovarian cancer with combination of paclitaxel and the carboplatin agents. In an attempt to define the genetic determinants for this variability, we are conducting a pharmacogenomics study to predict response based on patient genomics[3].

Candidate Gene in Predicting In Vivo Ovarian Cancer Response to Combination Therapy with Paraplatin and Paclitaxel